CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,346	$ 11,464
Marketable debt securities	513	816
Receivables	10,747	10,921
Inventories	2,557	2,662
Other current assets	5,617	5,907
Total Current assets	29,780	31,770
Property, plant and equipment	7,136	6,646
Goodwill	21,719	21,169
Other intangible assets	23,307	27,072
Deferred income taxes	4,236	2,768
Marketable debt securities	320	364
Other non-current assets	6,105	5,370
Total Assets	92,603	95,159
Current liabilities:
Short-term debt obligations	2,046	3,119
Accounts payable	3,602	3,259
Other current liabilities	18,126	15,884
Total Current liabilities	23,774	22,262
Deferred income taxes	369	338
Long-term debt	47,603	36,653
Other non-current liabilities	4,469	6,421
Total Liabilities	76,215	65,674
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2868 in 2024 and 2,953 in 2023, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2024 and 2023	292	292
Capital in excess of par value of stock	46,024	45,684
Accumulated other comprehensive loss	(1,238)	(1,546)
Retained earnings	14,912	28,766
Less cost of treasury stock — 894 million common shares in 2024 and 902 million common shares in 2023	(43,655)	(43,766)
Total BMS Shareholders’ Equity	16,335	29,430
Noncontrolling interest	53	55
Total Equity	16,388	29,485
Total Liabilities and Equity	$ 92,603	$ 95,159
Preferred stock, shares outstanding (in shares)	2,868	2,953
Preferred stock, shares issued (in shares)	2,868	2,953